Cyclerion Therapeutics (CYCN) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $4.6 million.
- Cyclerion Therapeutics' Cash & Equivalents rose 5905.29% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 5905.29%. This contributed to the annual value of $3.2 million for FY2024, which is 5731.08% down from last year.
- Cyclerion Therapeutics' Cash & Equivalents amounted to $4.6 million in Q3 2025, which was up 5905.29% from $3.0 million recorded in Q2 2025.
- In the past 5 years, Cyclerion Therapeutics' Cash & Equivalents registered a high of $70.4 million during Q2 2021, and its lowest value of $2.9 million during Q3 2024.
- Its 5-year average for Cash & Equivalents is $20.6 million, with a median of $7.6 million in 2023.
- As far as peak fluctuations go, Cyclerion Therapeutics' Cash & Equivalents crashed by 8256.78% in 2023, and later skyrocketed by 5905.29% in 2025.
- Over the past 5 years, Cyclerion Therapeutics' Cash & Equivalents (Quarter) stood at $54.0 million in 2021, then plummeted by 75.2% to $13.4 million in 2022, then plummeted by 43.42% to $7.6 million in 2023, then tumbled by 57.31% to $3.2 million in 2024, then skyrocketed by 41.34% to $4.6 million in 2025.
- Its Cash & Equivalents stands at $4.6 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.6 million for Q1 2025.